Be a part of history in the making for type 1 diabetes research
On Nov. 17, 2022, the U.S. Food and Drug Administration (FDA) weighed the evidence for teplizumab to delay type 1 diabetes (T1D) in at-risk individ...
On Nov. 17, 2022, the U.S. Food and Drug Administration (FDA) weighed the evidence for teplizumab to delay type 1 diabetes (T1D) in at-risk individuals, and the T1D community got a big win: approved, under the brand name TzieldTM. Tzield (teplizumab-mzwv) is the first disease-modifying therapy for individuals at-risk for developing T1D. At-risk means that they exhibited two+ T1D-related autoantibodies — antibodies against one's own self – and their blood glucose is starting to be abnormal, but they have not yet become insulin dependent.